Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




GRAIL Partners with Epic to Integrate Multi-Cancer Test into EHR

By LabMedica International staff writers
Posted on 08 Apr 2026

GRAIL’s Galleri multi-cancer early detection (MCED) test is being integrated into Epic’s electronic health record (EHR) platform through Epic Aura. More...

The collaboration is designed to let clinicians at interested health systems order the test at the point of care, receive results, and manage follow-up within native EHR workflows. The integration is expected to enable approximately 450 health systems to deliver Galleri results within their existing patient portals, aiming to reduce administrative burden and manual processes while improving provider and patient experience.

Galleri is a proactive screening tool performed from a simple blood draw and is described as capable of detecting more than 50 cancer types before symptoms appear. The assay is supported by GRAIL’s targeted methylation-based platform and provides a cancer signal of origin prediction with high accuracy to guide diagnostic work-up when a signal is detected. It is described as the only available MCED test with demonstrated performance in patients screened for cancer. The test requires a prescription and is intended to complement, not replace, recommended screenings; it is recommended for adults with an elevated risk for cancer, such as those aged 50 years and older.

Implementation planning began in the first quarter of 2026 with initial integrations and early adopter programs. GRAIL is working with Epic and Amazon Web Services (AWS) to support workflow alignment, training, and deployment, with broad availability expected by the end of 2026.

“Today, recommended screening exists for only five cancers in the U.S., yet more than 70% of deaths are caused by cancers without a recommended screening test. With a scalable integration through Epic, we are reducing operational barriers and making it easier for healthcare providers to incorporate the Galleri test into routine care, with the ultimate goal of supporting early cancer detection before symptoms appear, when outcomes may be better,” said Josh Ofman, MD, MSHS, President at GRAIL.

“Aura helps healthcare organizations collaborate by removing administrative barriers. With GRAIL joining the Epic community, together with healthcare organizations, we can advance early detection and ultimately improve cancer survival rates,” said Alan Hutchison, Vice President at Epic.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Silver Member
Vitamin D Assay
EZ Vitamin D Assay
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Blood Protein Analysis Reveals Menopause-Associated Signals of Brain Aging

Menopause affects women across midlife and is often accompanied by endocrine changes, hot flashes, brain fog and sleep disturbances. Women spend roughly one third of their lives after the menopause transition,... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI-Supported Approach May Improve Cervical Cancer Screening in Low-Resource Settings

Cervical cancer screening coverage often remains below 15% in low- and middle-income countries. Limited accuracy of visual inspection with acetic acid, together with uneven access to high-quality human... Read more

Hematology

view channel
Image: Mayo Clinic researchers used genetic data from nearly 50,000 participants to identify sickle cell and beta-thalassemia carrier traits, highlighting how population-scale testing can complement existing screening (Image Credit: Adobe Stock)

Genetic Testing Offers Opportunities for Earlier Blood Disorder Carrier Identification

Inherited hemoglobin disorders can affect oxygen transport, yet individuals who carry only a trait may remain unaware of their status. People with sickle cell trait or beta-thalassemia trait often have... Read more

Microbiology

view channel
Image: Four-quadrant streaking of fecal samples on chromogenic UTI agar shows various patterns of relative bacterial species abundance. The assorted shapes of the pinkish colonies indicate different E. coli strains. (Photo courtesy of Sokurenko Lab)

Stool Testing Predicts UTI Risk and Guides Antibiotic Selection

Urinary tract infections (UTIs) are a common reason for antibiotic prescribing in general medical practice and can be painful in postmenopausal women, sometimes progressing to kidney infection or life-threatening... Read more

Pathology

view channel
AI: Artificial intelligence; CNN: Convolutional neural networks; ResNet: Residual neural network. (Xing-hua Gao from The First Hospital of China Medical University, China Image Source Link: https://www.ovid.com/jnls/cmj/fulltext/10.1097/cm9.0000000000004154~deep-learning-based-computational-pathology-technologies)

Review Highlights Progress and Validation Needs for AI in Digital Pathology

Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.